In biotech, there is typically something called speculative value. NWBO has not been the recipient of speculative valuation for over five years, because no one can determine timelines. Consequently pre-result speculative valuation has been non-existent for the most part.
On the other hand, post result speculative value after results (if decent) and after (any) approval will be high. The reason for this is proof of concept and thereafter marketability can the translate into speculation for global distribution, other likely treatable indications in the future and DC Direct’s capacity. The issues of automated closed system are essentially solved.
speculative valuation after results + speculation after (likely) approval + revenue multiple + speculation over potential buyout.
Cancer will be detected earlier in years and decades going forward because of new and increasing blood test innovation. DCVax is likely to reboot our immune systems without the need for side effects. The earlier one spots cancer, the more likely successful treatment will follow.
Market Data 
Markets 
AI
